{"id":827467,"date":"2025-03-19T08:13:02","date_gmt":"2025-03-19T12:13:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/"},"modified":"2025-03-19T08:13:02","modified_gmt":"2025-03-19T12:13:02","slug":"theriva-biologics-to-present-at-the-2025-neauxcancer-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/","title":{"rendered":"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCKVILLE, Md., March  19, 2025  (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company\u2019s Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.<\/p>\n<p align=\"justify\">A company presentation will take place during the conference\u2019s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference\u2019s Innovation track spotlights the most promising emerging biotech and healthcare companies advancing detection, treatment, and cures across critical oncology areas.<\/p>\n<p align=\"justify\">Theriva\u2019s management team will be available for one-on-one meetings during the conference, interested investors should contact Theriva\u2019s investor relations representative as below.<\/p>\n<p align=\"justify\">\n        <strong>About Theriva\u2122 Biologics,\u00a0Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Theriva\u2122 Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient\u2019s immune system. The Company\u2019s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7uXDTcnBgBhcC55p-PI0wj6EMj0zSqLqmkPE5xVVOfYTcNG01lPjcDrGF8sPuvwaz0yWWUs8h_vXiXgpqlyiFhBvSxaRFXXngJzVfEY8DHg=\" rel=\"nofollow\" target=\"_blank\">www.therivabio.com<\/a>. \u00a0<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\u00a0<br \/><strong>Investor Relations:<\/strong>\u00a0<br \/>Kevin Gardner<br \/>LifeSci Advisors, LLC\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rglr-B7PBw73JEr1EyFR_9pjy3Q3ibzFb6hAh0g1AUzR_K1OAw490hnHkFU2G1xth8etrmghfHaQ-8G286LyK4kPe1hYXL5W54UaUHw2eT0tWY6WH1LXIaA9gj4rq9qu\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><br \/>617-283-2856<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTYyNmZjYWYtMmRlZC00YWY4LThlOTItMmZkZWJhMTAwZTU2LTUwMDEwMTU4MS0yMDI1LTAzLTE5LWVu\/tiny\/Theriva-Biologics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company\u2019s Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. A company presentation will take place during the conference\u2019s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference\u2019s Innovation track spotlights the most promising emerging biotech and healthcare companies advancing detection, treatment, and cures across critical oncology areas. Theriva\u2019s management team will be available for one-on-one meetings during the conference, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827467","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company\u2019s Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. A company presentation will take place during the conference\u2019s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference\u2019s Innovation track spotlights the most promising emerging biotech and healthcare companies advancing detection, treatment, and cures across critical oncology areas. Theriva\u2019s management team will be available for one-on-one meetings during the conference, &hellip; Continue reading &quot;Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T12:13:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference\",\"datePublished\":\"2025-03-19T12:13:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/\"},\"wordCount\":358,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/\",\"name\":\"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==\",\"datePublished\":\"2025-03-19T12:13:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/","og_locale":"en_US","og_type":"article","og_title":"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference - Market Newsdesk","og_description":"ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Company\u2019s Management will be attending and presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. A company presentation will take place during the conference\u2019s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference\u2019s Innovation track spotlights the most promising emerging biotech and healthcare companies advancing detection, treatment, and cures across critical oncology areas. Theriva\u2019s management team will be available for one-on-one meetings during the conference, &hellip; Continue reading \"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T12:13:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference","datePublished":"2025-03-19T12:13:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/"},"wordCount":358,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/","name":"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==","datePublished":"2025-03-19T12:13:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjQ1OCM2ODExNzQ5IzUwMDEwMTU4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-present-at-the-2025-neauxcancer-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Theriva\u2122 Biologics to Present at the 2025 NeauxCancer Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827467"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827467\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}